Chc Healthcare Group · TWSE:4164
Chc Healthcare — Investor Presentation (March 2014)
29 slides from Chc Healthcare's investor presentation, March 2014
Slide 1: CHC Healthcare Group
WY AE yp ViRRUARAA | CHC HEALTHCARE GROUP 4164 TT March , 2014
Slide 2: Disclaimer
Disclaimer • The information contained in this confidential document ("Presentation") has been prepared by CHC Health Care Group (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment. • While the information contained herein has been prep
Slide 3: Company Milestones
Company Milestones 2013 2009 2011 2012 2006 •Founded •Set up •Greater Exclsive CHC Guangzhou China Sole Distributor •Established for IBA 2004 Ophthalmology Healthcare ChiuHo Co. Distributor Proton Group of Swissray 2003 Became Dept. •Listed in Therapy •Exclusive Taiwan System 1999 •Started sole •Rep
Slide 4: Strength of CHC
Strength of CHC Exclusive distributor • Exclusive distributor for top global brands: Oncology -- Elekta、TomoTherapy； for top Nuclear Medicine and Diagnostic Imaging Equipments –GE；Radiological Imaging global Equipment – Swissray and top brands for Ophthalmology and Dentistry。 brands with high market
Slide 5: Full Spectrum of Services Provider
Full Spectrum of Services Provider Manufacturer Clinic Planning Product Categories: Specialty Site Radiotherapy Construction Neurology CHC Health Care Group Operational Ophthalmology Consulting Dentistry Revenue Distribution Services Installation Sharing Diagnostic Imaging Partnerships Education & N
Slide 6: Radiotherapy is our focus
Radiotherapy is our focus Radiotherapy sales, revenue 7% of sales are derived from sharing partnerships and value- ophthalmology & dentistry- added services in Taiwan related equipment and accounted for 93% of 2012 supplements. revenue. Radiotherapy Sales, 24% Dentistry, 1% The superior Ophthamology
Slide 7: Value-Added Services with a Robust Distribution Channel
Value-Added Services with a Robust Distribution Channel • CHC's equipment is used in 52 of the 68 local hospitals that have radiotherapy departments. • 12-15 year • Our market share for Brachytherapy Direct radiotherapy equipment is 90%+. equipment Selling revenue-sharing agreements are increasing,
Slide 8: We work with world-renowned brands
We work with world-renowned brands… Radiotherapy and Nuclear Medicine & Ophthalmology and Neurology Diagnostic Imaging Dentistry 8
Slide 9: Manufacturers Certified Service Team
Manufacturers Certified Service Team CHC’s experienced consulting and service team is a critical factor in our success. Manufacturers rely on CHC to provide this operational support and after-sales service. CHC’s 30 years of investment in establishing, training and re-certifying its 60+ member team
Slide 10: CHC's Competitive Advantage in China
CHC’s Competitive Advantage in China Complete Product Line Successful Taiwan Experience Beijing Full Service Solution Capability Clinical Education and Training Hunan Flexible Sales Model Fujian Guangxi Guangdong Cross-strait Medical Conferences Hainan
Slide 11: CHC's China Strategy
CHC’s China Strategy • Top sales professionals with rich China experience. • Building up franchise in areas of China that are demographically similar to Taiwan. (for Elekta products) • Targeting Grade 3 hospitals in first tier cities. (for Novadaq and Swissray’s products) • Using old business networ
Slide 12: Radiotherapy Equipment Market in China
Radiotherapy Equipment Market in China • There are about 1,300 Class Ⅲ hospitals in Hospitals China. 7 of the Top 10 clinics use Elekta. ClassⅢ (~1,300) >500 beds Class Ⅱ • China is the third largest medical device hospitals market in the world and domestic (~6,000) > 100 beds manufacturers’ product
Slide 13: High Demand for Radiotherapy Services
High Demand for Radiotherapy Services Cancer Radiotherapy application rate in Taiwan and western countries 28.40% Cardio vascular diseases 80% Cerebral vascular diseases 70% 23.30% 60% Pneumonia Diabetes 50% 2.80% Injuries 40% 3.20% Chronic lower respiratory diseases 30% Unmet 3.20% 11.10% Hypertens
Slide 14: Diagnostic Imaging Products Account for Over 25% of the Global Medical Device Market
Diagnostic Imaging Products Account for Over 25% of the Global Medical Device Market Global Medical Device market breakdown Global Diagnostic Imaging Market breakdown Medical supply, 14.60% Bone densitometer, Others, 30.30% 2.00% Other, 0.70% CT, 9.80% X ray, 31.70% Diagnotic Imaging, 25.80% PET, 17
Slide 15: Product Diversification
Product Diversification Proton therapy (DR X-Ray) Fluorescence Imaging 15
Slide 16: ddR Systems
Swissray =" dd'R Systems 16
Slide 17: High end Digital Xray
High end Digital Xray 17
Slide 18: Proton Pencil Beam Scanning
Proton Pencil Beam Scanning Proton Therapy 18
Slide 19: Protons and Charged Particles
Protons and Charged Particles Protons give Conformal Dose and Low Integral Dose 19
Slide 20: Proton Design Flexibility
Proton Design Flexibility ProteusPLUS TM ProteusONE TM UNIVERSAL PROTON THERAPY SOLUTION COMPACT PROTON THERAPY SOLUTION Active and Passive treatment modes Active treatment only Profitable PT center for 1/6 the size 1800 m² 300 m² 20
Slide 21: Clinically Relevant Imaging
Clinically Relevant Imaging SPY® Fluorescence Imaging Technology Imaging agent administered IV; binds to blood protein; circulates in vessels and perfuses tissue Agent fluoresces when exposed to laser light - images are captured and displayed on devices Provides accurate real-time review of pe
Slide 22: A New Paradigm – New Imaging Modalities Specially Suitable for Surgery
A New Paradigm – New Imaging Modalities Specially Suitable for Surgery 1. Fluorescence Imaging – real time visualization a. Perfusion and Vascular flow b. Near surface Lymph node mapping c. Nerve 2. Auto-fluorescence a. Cancer margins in hollow organs: Lung, GI track, … 3. Intra-operative visualizat
Slide 23: One Technology – Multiple Comprehensive Apps.
One Technology – Multiple Comprehensive Apps. Endoscopic Diagnostic Imaging Surgery Wound Care Robotic Open Surgery Firefly
Slide 24: Financial Highlights
Financial Highlights 2,100,000 1,800,000 1,500,000 1,200,000 Sales 900,000 Gross Profit 600,000 Op Profit 300,000 Net Profit 0 2009 2010 2011 2012 2013 Jan- NT$ ‘000 Sep 2009 2010 2011 2012 2013 Jan-Sep Sales 959,795 1,867,510 1,995,368 1,989,670 1,418,372 Gross Profit 264,987 778,153 923,272 833,82
Slide 25: Financial Highlights
Financial Highlights Revenue Gross Profit & Gross Margin 50% 2,500,000 1,400,000 46.3% 45% 41.7% 41.9% 1,995,368 1,989,670 1,200,000 40% 2,000,000 1,867,510 923,272 35% 1,000,000 833,824 30% 1,500,000 778,153 800,000 27.6% 25% 959,795 600,000 20% 1,000,000 15% 400,000 264,987 500,000 10% 200,000 5%
Slide 26: Product Consolidation
Product Consolidation Cancer Center Consulting & Management(Taiwan、China、Indonesia、Cambodia) IBA Proton Therapy Swissray Radiological Imaging Equipment (Greater China) Product Pipeline Novadaq SPY Fluorescence Imaging Technology (Greater China) White Essence Dental Clinic (Exclusive Greater China Di
Slide 27: Peer Comparison Charts
Peer Comparison Charts ROE Operating Margin 35% 80% 30% 60% 25% 23.0% 40% 37.1% 20% 32.5% 20.1% 28.3% 15% 20% 12.8% 12.8% 10% 5.8% 0% 5% 2009 2010 2011 2012 0% -20% -5% 2009 2010 2011 2012 -40% -10% -15% -60% CHC Pacific Hospital CCM Cowealth CHC Pacific Hospital CCM Cowealth Net Margin NT$ EPS 50%
Slide 28: We Aim to Become the Leading Medical Equipment Full Service Solutions Provider in the Asia-Pacific Region
We Aim to Become the Leading Medical Equipment Full Service Solutions Provider in the Asia-Pacific Region Belgium Sweden Germany USA Swiss USA Japan Swiss Germany Canada Nederland USA Germany Israel USA Germany 28 28
Slide 29: Thank you
CHC HEALTHCARE GROUP GY KEE VieMDARAA
CHC Healthcare Group — Investor Presentation (March 2014) on 6ix